IBIO Valuation

iBio Inc

Add to Watchlist

Advanced Chart

1.320

-0.07(-5.036%)1D

IBIO Relative Valuation

IBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IBIO is overvalued; if below, it's undervalued.

Historical Valuation

iBio Inc (IBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.32 is considered Fairly compared with the five-year average of -4.19. The fair price of iBio Inc (IBIO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.32

Fair

-5.01

Trailing

Forward

0.00

EV/EBITDA

iBio Inc. (IBIO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.75

EV/EBIT

iBio Inc. (IBIO) has a current EV/EBIT of -0.75. The 5-year average EV/EBIT is -2.19. The thresholds are as follows: Strongly Undervalued below -7.12, Undervalued between -7.12 and -4.66, Fairly Valued between 0.28 and -4.66, Overvalued between 0.28 and 2.74, and Strongly Overvalued above 2.74. The current Forward EV/EBIT of -0.75 falls within the Historic Trend Line -Fairly Valued range.

1.32

iBio Inc. (IBIO) has a current PS of 1.32. The 5-year average PS is 74.61. The thresholds are as follows: Strongly Undervalued below -117.21, Undervalued between -117.21 and -21.30, Fairly Valued between 170.52 and -21.30, Overvalued between 170.52 and 266.43, and Strongly Overvalued above 266.43. The current Forward PS of 1.32 falls within the Historic Trend Line -Fairly Valued range.

-1.26

P/OCF

iBio Inc. (IBIO) has a current P/OCF of -1.26. The 5-year average P/OCF is -0.32. The thresholds are as follows: Strongly Undervalued below -2.42, Undervalued between -2.42 and -1.37, Fairly Valued between 0.72 and -1.37, Overvalued between 0.72 and 1.77, and Strongly Overvalued above 1.77. The current Forward P/OCF of -1.26 falls within the Historic Trend Line -Fairly Valued range.

-1.02

P/FCF

iBio Inc. (IBIO) has a current P/FCF of -1.02. The 5-year average P/FCF is -0.17. The thresholds are as follows: Strongly Undervalued below -1.23, Undervalued between -1.23 and -0.70, Fairly Valued between 0.36 and -0.70, Overvalued between 0.36 and 0.90, and Strongly Overvalued above 0.90. The current Forward P/FCF of -1.02 falls within the Undervalued range.

iBio Inc (IBIO) has a current Price-to-Book (P/B) ratio of 1.72. Compared to its 3-year average P/B ratio of 0.89 , the current P/B ratio is approximately 92.32% higher. Relative to its 5-year average P/B ratio of 1.31, the current P/B ratio is about 31.13% higher. iBio Inc (IBIO) has a Forward Free Cash Flow (FCF) yield of approximately -57.30%. Compared to its 3-year average FCF yield of -285.77%, the current FCF yield is approximately -79.95% lower. Relative to its 5-year average FCF yield of -186.67% , the current FCF yield is about -69.30% lower.

1.72

P/B

Median3y

0.89

Median5y

1.31

-57.30

FCF Yield

Median3y

-285.77

Median5y

-186.67

Competitors Valuation Multiple

The average P/S ratio for IBIO's competitors is 2.96, providing a benchmark for relative valuation. iBio Inc Corp (IBIO) exhibits a P/S ratio of 1.32, which is -55.38% above the industry average. Given its robust revenue growth of 14.29%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MIRA Pharmaceuticals Inc

Paranovus Entertainment Technology Ltd

Performance Decomposition

Market capitalization of IBIO decreased by 55.10% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.85K to -2.58K.

The secondary factor is the Revenue Growth, contributed 14.29%to the performance.

Overall, the performance of IBIO in the past 1 year is driven by Margin Expansion. Which is more sustainable.

14.29%

175.00K → 200.00K

Revenue Growth

39.17%

-1.85K → -2.58K

Margin Expansion

-108.56%

8.81 → -0.75

P/E Change

-55.10%